GlassScriptPhysician profile
Fallon Smith Hall
NPI 1306412960
$3,112.32
in general payments reported to CMS, 2019-2025
28 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $563 · 2023: $1,423 · 2024: $719 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.35 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.65 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $349.49 | 2022-2023 | Hetlioz, Fanapt |
| Amgen INC. | $320.35 | 2022-2024 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $268.87 | 2023-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.95 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $113.58 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $101.99 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Antares Pharma, INC. | $98.53 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.42 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $95.71 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $93.91 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $75.78 | 2022-2023 | |
| Pfizer INC. | $73.36 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $61.86 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $59.69 | 2023-2024 | Rexulti, Abilify Maintena, Jynarque |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $52.95 | 2023 | |
| Lundbeck LLC | $51.95 | 2022-2023 | Rexulti |
| Almatica Pharma LLC | $51.12 | 2023 | Loreev Xr |
| Aimmune Therapeutics, INC. | $44.27 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.48 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $31.26 | 2024 | Auvelity |
| Impel Pharmaceuticals INC. | $28.22 | 2023 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $27.69 | 2023 | Edarbi |
| Corcept Therapeutics | $16.45 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $16.43 | 2023 | |
| Inogen, INC. | $15.40 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Esperion Therapeutics, INC. | $15.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fallon Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.